Trasplante de microbiota fecal

García-García-de-Paredes, Ana; Santiago, Enrique Rodríguez de; Aguilera, Lara; Ferre‐Aracil, Carlos; López-Sanromán, Antonio

doi:10.1016/j.gastrohep.2014.07.010

Cited by 13 publications

(7 citation statements)

References 96 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…TBP, though rare in developed countries with an occurrence rate of roughly 1%, presents significant clinical challenges due to its high mortality rate [ 1 , 7 ]. The disease’s protean presentations, which include pericardial effusion, constrictive pericarditis, and a complex scenario combining both effusion and constriction, add to the diagnostic conundrum [ 7 , 8 ].…”

Section: Discussionmentioning

confidence: 99%

“…Rifampicin, isoniazid, ethambutol, and pyrazinamide, which comprise the first-line anti-tuberculosis medications, are typically administered concurrently for an intensive 2-month period. The treatment then follows for 4 more months with isoniazid and rifampin [ 1 ]. In situations with large pericardial effusions or tamponade, pericardiocentesis can be lifesaving.…”

Section: Discussionmentioning

confidence: 99%

“…Tuberculosis, an infectious disease predominantly caused by Mycobacterium tuberculosis , is a major global health concern. Despite efforts towards eradication, it continues to burden many regions of the world, particularly in low- and middle-income countries [ 1 ]. Primarily a pulmonary disease, tuberculosis can disseminate to involve other parts of the body, demonstrating a wide array of clinical manifestations [ 2 ].…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Tuberculous Pericarditis Presenting as Cardiac Tamponade: Role of Echocardiography

Khatun,

Akivis,

et al. 2023

J Med Cases

View full text Add to dashboard Cite

Tuberculous pericarditis, a rare but potentially lethal manifestation of tuberculosis, poses diagnostic and therapeutic challenges in clinical practice. Its nonspecific clinical presentation often mimics other conditions, leading to delayed or missed diagnoses. We report a 25-year-old male with no past medical history, who presented with nonspecific symptoms such as fatigue, weight loss, body aches, and dyspnea. An electrocardiogram showed low voltage QRS complex with electrical alternans, and transthoracic echocardiography (TTE) showed large pericardial effusion with tamponade physiology with right ventricular diastolic collapse, the collapse of the right atrium and the inferior vena cava was dilated with a respiratory variation of less than 50%. The diagnosis of tuberculous pericarditis was made based on clinical presentation, imaging, and laboratory findings, including a positive QuantiFERON-TB gold test and pericardial fluid analysis, despite negative cultures. This case highlights the significance of considering tuberculosis in the differential diagnosis of pericardial effusion and underscores the role of imaging and laboratory investigations in diagnosis. Management of tuberculous pericarditis involves a combination of antituberculous chemotherapy, pericardiocentesis, and corticosteroids. Despite its rarity, tuberculous pericarditis carries a high mortality rate and can present as cardiac tamponade, as illustrated in our case. This underscores the need for high clinical suspicion, especially in high-risk populations, for timely diagnosis and initiation of treatment.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Tuberculous Pericarditis Presenting as Cardiac Tamponade: Role of Echocardiography

Khatun,

Akivis,

et al. 2023

J Med Cases

View full text Add to dashboard Cite

show abstract

“…The study by Garcia-Garcia-de-Paredes et al reported the resolution of diarrhea in 87% of patients with Clostridium difficile infection. FMT was superior to the use of antibiotics that attack the bacteria as well as damage the intestinal microbiota [ 40 ].…”

Section: Discussionmentioning

confidence: 99%

Fecal Microbiota Transplantation in Human Immunodeficiency Virus-Infected Patient Population: A Systematic Review and Meta-Analysis

Malik,

Malik

2023

Gastroenterol Res

View full text Add to dashboard Cite

Background Patients with human immunodeficiency virus (HIV) infection suffer from alterations in gut microbiota due to recurrent gastrointestinal infections and systemic inflammation. Fecal microbiota transplantation (FMT) appears to be a potential therapy; however, there are concerns about its safety. Likewise, no previous meta-analysis evaluated FMT efficacy in HIV-infected patients. Methods We conducted a thorough electronic search on PubMed, Scopus, OVID, Web of Science, and Cochrane CENTRAL for clinical studies assessing the safety and efficacy of FMT in patients with HIV and gastrointestinal dysbiosis, where FMT was indicated to restore the disrupted microbiota. Results FMT significantly restored the typical microbiome in patients with Clostridium difficile ( C. difficile ) and non- C. difficile and reduced the risk of gastrointestinal infections in HIV patients receiving antiretroviral therapy (odds ratio (OR) = 0.774, 95% confidence interval (CI): (0.62, 0.966)). Furthermore, adverse events, such as distention and bloating, associated with FMT were comparable between HIV and health controls (OR = 0.60, 95% CI: (0.07, 4.6)), with no statistical difference. Conclusions Current evidence demonstrated that FMT is safe and effective in HIV patients suffering from alterations in gut microbiota. We recommend further multi-centric clinical studies to address the optimal transplant amount and source for FMT. To the best of our knowledge, this is the first meta-analysis to assess the safety and efficacy of FMT in patients with HIV.

show abstract

“…Donor selection and screening criteria for FMT is not currently standardised, showing variability among studies. In this RCT, we will use the exclusion criteria and conduct the microbiological studies suggested by García-García-de-Paredes et al 26 and Huttner et al 16. To ensure double-blinding, only donors not related to the patients will be selected.…”

Section: Methods and Analysismentioning

confidence: 99%

Randomised, double-blind, placebo-controlled, phase 2, superiority trial to demonstrate the effectiveness of faecal microbiota transplantation for selective intestinal decolonisation of patients colonised by carbapenemase-producing Klebsiella pneumoniae (KAPEDIS)

et al. 2022

View full text Add to dashboard Cite

IntroductionInfections caused by carbapenemase-producing Enterobacterales are frequent and associated with high rates of mortality. Intestinal carriers are at increased risk of infection by these microorganisms. Decolonisation strategies with antibiotics have not obtained conclusive results. Faecal microbiota transplantation (FMT) could be an effective and safe strategy to decolonise intestinal carriers of KPC-producing Klebsiella pneumoniae (KPC-Kp) but this hypothesis needs evaluation in appropriate clinical trials.Methods and analysisThe KAPEDIS trial is a single-centre, randomised, double-blind, placebo-controlled, phase 2, superiority clinical trial of FMT for eradication of intestinal colonisation by KPC-Kp. One hundred and twenty patients with rectal colonisation by KPC-Kp will be randomised 1:1 to receive encapsulated lyophilised FMT or placebo. The primary outcome is KPC-Kp eradication at 30 days. Secondary outcomes are: (1) frequency of adverse events; (2) changes in KPC-Kp relative load within the intestinal microbiota at 7, 30 and 90 days, estimated by real-time quantitative PCR analysis of rectal swab samples and (3) rates of persistent eradication, KPC-Kp infection and crude mortality at 90 days. Participants will be monitored for adverse effects throughout the intervention.Ethics and disseminationEthical approval was obtained from Reina Sofía University Hospital Institutional Review Board (approval reference number: 2019-003808-13). Trial results will be published in peer-reviewed journals and disseminated at national and international conferences.Trial registration numberNCT04760665.

show abstract

Trasplante de microbiota fecal

Cited by 13 publications

References 96 publications

Tuberculous Pericarditis Presenting as Cardiac Tamponade: Role of Echocardiography

Tuberculous Pericarditis Presenting as Cardiac Tamponade: Role of Echocardiography

Fecal Microbiota Transplantation in Human Immunodeficiency Virus-Infected Patient Population: A Systematic Review and Meta-Analysis

Randomised, double-blind, placebo-controlled, phase 2, superiority trial to demonstrate the effectiveness of faecal microbiota transplantation for selective intestinal decolonisation of patients colonised by carbapenemase-producing Klebsiella pneumoniae (KAPEDIS)

Contact Info

Product

Resources

About